Accelerate to discover

Back to filter

Related topics

Introducing Cytek Cloud

Cytek Biosciences

Dec 1, 2022

Cytek Cloud is the new digital ecosystem that supports full spectrum flow cytometry research from panel design to data...

See More, Sort More with Cytek Full Spectrum Systems

Cytek Biosciences

Nov 28, 2022

Still wondering whether to join the shift to full spectrum cytometry?  Easily transfer assays from your Cytek Northern...

Demonstrate the value of RareCyte Orion system via web-based Minerva viewer

RareCyte

Nov 25, 2022

The HTA CRC Atlas X dataset contains images and other data being used for construction of an atlas of human colorectal...

ACCELA Educational webinar series: Unlocking Spatial Biology with RareCyte Orion Technology

RareCyte

Nov 16, 2022

Discover full slide, high-plex biomarker quantitation with the all-in-one spatial biology...

Dec 9, 2022

Practical aspects of an imaging study: live in vivo scanning

MOLECUBES

Nov 11, 2022

In this webinar, MOLECUBES will present a live in vivo demonstration, showing the entire workflow from animal...

All inside your incubator: xCELLigence eSight

Agilent technologies

Nov 3, 2022

Multiplex Live cell imaging and real-time biosensor measurement with xCELLigence eSight

Download the newest AVATAR data presented at CAR-TCR

Xcell Biosciences

Oct 21, 2022

Xcell Bio CSO, James Lim, presented new data showcasing improved potency of AVATAR-expanded CAR T cells and highlighted...

Dec 9, 2022

RareCyte Orion system advances Multi-modal digital pathology for colorectal cancer diagnosis

RareCyte

Oct 19, 2022

Precision medicine is critically dependent on better methods for diagnosing and staging disease and predicting drug...

Show all topics (10)

Heterodimeric compounds with dual-targeting active against both HIV and tuberculosis.

Jun 4, 2018

Both HIV and Tuberculosis are considered to be one of the most dangerous infectious diseases in the world. Quite often these two pathogens work in synchrony, making the risk of patient´s death twice as high. To solve this problem researchers from the Engelhardt Institute of Molecular biology in Russia cooperated with the National Institute of Health in the USA. They created compounds with dual activity against both pathogens by creating a heterodimer based on nucleosides. These heterodimers have two active components with two different rates of release based on the speed of their hydrolysis. They tested five of such compounds on HIV and Tuberculosis strain MS-114, which is drug-resistance. Drug-resistance of tuberculosis is one of the main problems in the treatment nowadays.

The compounds were judged based on the ability to inhibit these pathogens. Additionally, a testing on the host tissue was done using NovoCyte. The researchers tested the viability of mammalian lymphoid tissue after treatment. The results show that the heterodimers are non-toxic and non-static towards the cells while maintaining the potency against the pathogens. So far the compound was tested in vivo and ex vitro and seem to be a very promising solution. These results bring interesting insight and novel approach toward treatment of both HIV and Tuberculosis.

Want to know more?

Scientific paper
Application

Related technologies: Conventional flow cytometry

Brand profile

Agilent technologies

Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.

Related products

The best in class personalized flow cytometer

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey